Legend Biotech Corp

Key metrics

Key statistics

Latest filings

Browse the full filing history (343 filings)

Recent press releases

• Legend Biotech Announces Presentations at ASCO 20262026-05-21

  Preliminary results from Phase 1 data for LB2102 to reinforce early evidence of activity in solid tumors in a rapid oral presentation

• Legend Biotech Reports First Quarter 2026 Results and Recent Highlights2026-05-12

  CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 million

• Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth2026-05-04

  Leading experts across cell therapy, oncology, and immunology will provide strategic input as Legend advances and expands beyond its current portfolio

• Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results2026-04-28

  During the conference call and accompanying webcast, senior management will provide an overview of quarterly financial performance.

• Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights2026-03-10

  CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectively

Similar companies

The largest companies sharing Legend Biotech Corp's SEC industry classification (pharmaceutical preparations).